Welcome to our dedicated page for Corbus Pharmaceu news (Ticker: CRBP), a resource for investors and traders seeking the latest updates and insights on Corbus Pharmaceu stock.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) is a clinical-stage biopharmaceutical company advancing targeted therapies in precision oncology and metabolic disorders. This page serves as the definitive source for CRBP news, offering investors and researchers timely updates on scientific advancements and corporate developments.
Access verified information on clinical trial progress, regulatory milestones, and strategic partnerships across CRBP's pipeline. Key focus areas include Nectin-4 targeting antibody-drug conjugates, TGFβ pathway inhibitors, and novel obesity treatments designed to address critical unmet medical needs.
Our curated news collection enables efficient tracking of CRBP's innovative approaches to drug development. Stay informed about emerging data from studies evaluating CRB-701 in solid tumors, CRB-601's impact on tumor microenvironments, and CRB-913's potential in weight management.
Bookmark this page for direct access to official press releases and third-party analyses. Regular updates ensure you maintain current awareness of CRBP's position at the forefront of precision medicine development.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) is set to host a virtual 'Meet the Expert' event on April 25, 2023, at 11:00 AM ET. The focus will be on CRB-601, an anti-integrin monoclonal antibody targeting Transforming Growth Factor β (TGFβ) in oncology. Featuring notable researchers Dr. Jeffrey Clarke and Dr. Joan Seoane, the session will highlight CRB-601's potential to inhibit tumor growth, as evidenced in non-clinical studies. The company plans to submit an Investigational New Drug (IND) application for CRB-601 in the latter half of 2023. This initiative underscores Corbus's commitment to advancing precision oncology by innovating treatments for serious illnesses.
Corbus Pharmaceuticals (NASDAQ: CRBP) recently showcased promising pre-clinical data for its drug CRB-601 at the 2023 AACR annual meeting. The study revealed that CRB-601, an avβ8 blocking antibody, demonstrated dose-dependent antitumor activity and significantly enhanced the efficacy of anti-PD-1 immunotherapy. Additionally, the IND submission for CRB-601 is on track for the second half of 2023. The findings highlighted a notable increase in immune cell populations within tumors, along with a blockade of the TGFβ signaling pathway. The combination therapy showed substantial tumor growth inhibition in pre-clinical models, suggesting a strong potential for CRB-601 in cancer treatment.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) announced that pre-clinical data for its avβ8 blocking antibody, CRB-601, has been accepted for presentation at the 2023 American Association for Cancer Research annual meeting in Orlando, FL, from April 14-19, 2023.
The poster presentation is titled CRB-601, an avβ8 blocking antibody, prevents activation of TGFβ and exhibits anti-tumor activity associated with immune cell remodeling of the tumor microenvironment and will occur on April 16, 2023, from 1:30 PM - 5:00 PM.
Corbus focuses on innovative treatments targeting well-understood biological pathways in cancer therapy.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) has announced significant advancements in its precision oncology pipeline, highlighted by the exclusive licensing of CRB-701, a next-generation Nectin-4 antibody-drug conjugate. CRB-701 is currently in Phase 1 trials in China, targeting advanced solid tumors. Additionally, the company is on track for an IND submission of CRB-601 in late 2023, showcasing promising pre-clinical data. Financially, Corbus reported a net loss of approximately $10.9 million for Q4 2022, slightly worsening from the previous year. Despite these losses, the company maintains $59.2 million in cash, sufficient to fund operations into mid-2024.
Corbus Pharmaceuticals (NASDAQ: CRBP) announced the appointment of Yong Ben, M.D., MBA, to its Board of Directors on March 6, 2023. Dr. Ben brings over 20 years of oncology experience, having led numerous clinical development programs, including drug approvals at renowned companies. His expertise in healthcare venture investment is expected to enhance Corbus' strategic capabilities. The company's recent license agreement for CRB-701 bolsters its position in precision oncology. Corbus aims to advance its pipeline, including CRB-701 and CRB-601, under Dr. Ben's guidance.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) announced that CEO Yuval Cohen, Ph.D., will present a corporate update and engage in one-on-one investor meetings at the Oppenheimer 33rd Annual Healthcare Conference, hosted virtually from March 13-15, 2023.
The presentation is scheduled for March 14, 2023, at 9:20 a.m. ET. Investors can access the webcast here.
Corbus focuses on precision oncology, with key products including CRB-701 and CRB-601 targeting cancer cells.
Corbus Pharmaceuticals Holdings has entered an exclusive licensing agreement with CSPC Pharmaceutical Group for the development of CRB-701, an antibody drug conjugate targeting Nectin-4. This drug is being developed for various cancers, including urothelial, lung, breast, and prostate. An upfront payment of $7.5 million will be made to CSPC, with potential milestone payments totaling $685 million. The agreement also includes a 1-for-30 reverse stock split effective February 14, 2023, aimed at maintaining compliance with Nasdaq's minimum bid price requirement of $1.00. Corbus aims to initiate US clinical trials in 2024.
FAQ
What is the current stock price of Corbus Pharmaceu (CRBP)?
What is the market cap of Corbus Pharmaceu (CRBP)?
